In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling drug by annual revenue in 2023, earning $22.2 billion by 2025, according to new research by GlobalData.

Adial's PK study satisfied an FDA requirement for the AD04 Phase 3 trial. Study confirmed AD04 can be taken with or without ...

AirPods are the best-selling model, but they're comparatively pricey and not always the best buy for iPhone users. So this is our hotly-contested pick of the best wireless earbuds your money can ...

Selling covered calls is an income-generating ... That's why you need to know the best stocks for covered calls when thinking about your investments. Knowing the strategy is only a part of the ...